These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29271103)

  • 1. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Polidori D; Argenti D; Di Prospero NA
    Pediatr Diabetes; 2018 Jun; 19(4):649-655. PubMed ID: 29271103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Iijima H; Kifuji T; Maruyama N; Inagaki N
    Adv Ther; 2015 Aug; 32(8):768-82. PubMed ID: 26280756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
    Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
    Devineni D; Polidori D
    Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
    Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E
    Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
    Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
    J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
    Zhang H; Zhu X; Li X; Chen H; Wu M; Li C; Liu J; Liu C; Zhang Y; Ding Y
    Diabetes Obes Metab; 2020 Feb; 22(2):191-202. PubMed ID: 31588657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
    Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
    Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.
    Mondick J; Riggs M; Sasaki T; Sarashina A; Broedl UC; Retlich S
    Diabetes Obes Metab; 2016 Mar; 18(3):241-8. PubMed ID: 26511213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin: A Review in Type 2 Diabetes.
    Deeks ED; Scheen AJ
    Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
    de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
    Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.